News

The lead investors in the transaction are Perceptive Life Sciences Fund, Quogue Capital, SCO Capital Partners and Versant Capital. Ron Bentsur, CEO of XTL, said: “We are very

Under the termination agreement, Novavax will complete the manufacture of remaining orders for the product and plans to close its Philadelphia manufacturing facility over the next few months.

Kosan said that it does not expect the termination of its collaborative research, development and commercialization agreement with Roche to impact its financial guidance for 2007 due to

This novel drug (Lu AA24530) discovered by Lundbeck, belongs to a new chemical class and represents an approach that is markedly different to any currently marketed antidepressants,according to

The company reported Q3 2007 net earnings of $858 million, or $0.43 per diluted share, compared to $338 million, or $0.17 per diluted share for the same period

The primary objectives of the trial include determining the minimum effective immunomodulatory dose of cyclophosphamide to obtain successful immune modulation. Secondary objectives include the safety profile of the

The data showed that 68% of the 34 patients evaluated for tumor response had clinical benefit. Ten patients had partial responses (eight confirmed, two not yet confirmed), and

The Horizons AMI trial compared Angiomax to heparin plus a platelet glycoprotein IIb/IIIa inhibitor (GPI) in more than 3,600 patients presenting with a heart attack. Horizons AMI demonstrated

The second-generation product, BSI-401, is BiPar’s new class of cancer therapies known as poly-ADP-ribose polymerase inhibitors. In animals with orthotopic human pancreatic tumors, BSI-401 significantly reduced tumor burden